It’s no secret that the realm of gene editing has the potential to transform the landscape of healthcare worldwide. This transformation spells out big opportunities for investors eyeing the burgeoning gene-editing sector.
One prominent player in this domain is CRISPR Therapeutics (NASDAQ:CRSP), which recently garnered attention after the U.S. FDA gave the green light for a groundbreaking gene-editing treatment for two genetic disorders. Riding the wave of innovation, CRSP’s stock surged from $40 to a high of $90 before recalibrating to $72.94, presenting a potentially lucrative opportunity as it gears up for a potential rally to $90. With an impressive pipeline targeting various health conditions, CRSP is positioned to soar as the gene editing market edges towards a whopping $29.9 billion by 2032, as projected by Precedence Research.
But CRISPR Therapeutics is just the tip of the iceberg. There are a trove of other gene-editing stocks brimming with potential. Here are three intriguing options that investors might want to take a closer look at.
Intellia Therapeutics (NTLA)
Source: rafapress / Shutterstock.com
As for Intellia Therapeutics (NASDAQ:NTLA), the stock grabbed attention after its Phase 1/2 study results of NTLA-2002 published in the New England Journal of Medicine heralded resounding success in treating hereditary angioedema. Embarking on Phase 3 trials for this treatment and progressing with other innovative therapies, NTLA is making significant strides in the realm of gene editing.
Verve Therapeutics (VERV)
Source: Yurchanka Siarhei/Shutterstock
Verve Therapeutics (NASDAQ:VERV) made waves with its VERVE-101 clinical trial, showcasing remarkable reductions in LDL-C levels for individuals grappling with HeFH. Endeavors such as the Heart-2 Phase 1b trial attest to Verve’s commitment to advancing genetic medicine, paving the way for groundbreaking therapies in the cardiovascular domain.
Global X Genomics & Biotechnology ETF (GNOM)
Source: Shutterstock
For those seeking diversified exposure in gene editing at a modest cost, the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) represents an enticing option. With a curated portfolio targeting companies in the gene-editing and biotechnology sphere, GNOM offers the potential for broad exposure to this dynamic sector with its 41 holdings, all at an accessible share price.
Why limit the potential of investing when you can embrace the full spectrum of opportunities that gene editing stocks have to offer? Delve into these innovative ventures and ride the wave of genetic revolution in healthcare. Who knows – you might just strike gold in the realm of gene editing investments.
On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
